伊马替尼治疗78例KIT变异的晚期黑色素瘤的疗效和安全性

发布时间：2018-03-30 14:50

  本文选题：KIT变异　切入点：伊马替尼　出处：《中国肿瘤生物治疗杂志》2017年03期

【摘要】：目的:旨在探讨酪氨酸激酶抑制剂伊马替尼在KIT突变/扩增的晚期黑色素瘤患者中的疗效及安全性。方法:回顾性分析2009年11月至2015年9月北京大学肿瘤医院肾病黑色素瘤科78例KIT突变/扩增的晚期黑色素瘤患者的临床资料,患者接受伊马替尼口服(400 mg/日)治疗,直至疾病进展或发生不能耐受的不良反应。结果:78例患者可评价疗效。全组患者客观缓解率22.4%,疾病控制率60.6%。17例部分缓解患者中,有11例为11或13号外显子突变。全组患者中位无疾病进展时间3.9个月(95%CI:2.1~5.8个月),中位总生存时间13.2个月(95%CI:10.1~16.3个月);1年生存率57%,2年生存率36%,3年生存率19%。最常见的不良反应包括水肿、乏力、食欲减退、皮疹、粒细胞下降(发生率均≥10%),未发现致命性药物不良反应。结论:伊马替尼治疗KIT突变/扩增的晚期黑色素瘤具有一定的疗效,且安全性良好。
[Abstract]:Objective: to investigate the efficacy and safety of imatinib, a tyrosine kinase inhibitor, in patients with advanced melanoma with KIT mutation / amplification. Methods: from November 2009 to September 2015, the kidney of Peking University Cancer Hospital was retrospectively analyzed. Clinical data of 78 patients with Advanced melanoma with KIT mutation / Amplification in melanoma. The patients were treated with imatinib (400 mg/) until the disease progressed or an intolerable adverse reaction occurred. Results the curative effect could be evaluated in 78 patients. The objective remission rate was 22.4and the disease control rate was 60.6.17 partial remission patients. There were 11 cases of exon 11 or 13 mutation. The median time of disease progression was 3.9 months and 95% CI: 2.1 ~ 5.8 months. The median survival time was 13.2 months. The median survival time was 13.2 months. The median survival time was 13.2 months. The 1-year survival rate was 57, the 2-year survival rate was 366,the 3-year survival rate was 199.The most common adverse reactions included edema. Fatigue, anorexia, rash, granulocyte decline (incidence 鈮，

本文编号：1686398